Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$0.03.

  • Harvard Bioscience's EPS (Basic) rose 7272.73% to -$0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.21, marking a year-over-year decrease of 26666.67%. This contributed to the annual value of -$0.28 for FY2024, which is 25615.44% down from last year.
  • As of Q3 2025, Harvard Bioscience's EPS (Basic) stood at -$0.03, which was up 7272.73% from -$0.05 recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's EPS (Basic) peaked at $0.06 during Q2 2022, and registered a low of -$1.14 during Q1 2025.
  • For the 5-year period, Harvard Bioscience's EPS (Basic) averaged around -$0.1, with its median value being -$0.03 (2023).
  • Over the last 5 years, Harvard Bioscience's EPS (Basic) had its largest YoY gain of 70000.0% in 2022, and its largest YoY loss of 181783.53% in 2022.
  • Over the past 5 years, Harvard Bioscience's EPS (Basic) (Quarter) stood at $0.01 in 2021, then crashed by 457.3% to -$0.05 in 2022, then increased by 23.45% to -$0.04 in 2023, then surged by 102.87% to $0.0 in 2024, then tumbled by 2712.28% to -$0.03 in 2025.
  • Its EPS (Basic) was -$0.03 in Q3 2025, compared to -$0.05 in Q2 2025 and -$1.14 in Q1 2025.